Abbott (NYSE:ABT) faces a proposed class action lawsuit related to alleged tracking tools used with its FreeStyle Libre ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device ...

Abbott has announced the U.S. availability of Lingo, the company’s first glucose monitoring system available without ...

Both of Abbott's over-the-counter CGMS are based on its popular FreeStyle Libre sensor technology, as Dexcom's prescription-free Stelo follows the popular G6 and G7 CGM technology for people who ...

Lingo is based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology 1, now used by more than 6 million people with diabetes globally 1. "There is a great deal of ...

Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings.

Designed to track glucose in real time, Lingo is based on Abbott's FreeStyle Libre CGM technology ... It is also accessible in the UK. Per a Grand View Research report, the global CGM devices ...

Abbott’s FreeStyle Libre devices involve a small sensor applied ... Abbott’s industry partners seem to view these collaborations in the same way. Que Dallara, president of Medtronic Diabetes ...

The iLet will soon connect to Abbott's FreeStyle Libre ® 3 Plus continuous glucose sensor, where readings every minute will help the iLet calculate insulin doses. Traditional setup and settings are ...

Abbott Labs' key product line in its diabetes care segment is the FreeStyle Libre, a portfolio of continuous glucose monitoring (CGM) devices that allow diabetes patients to keep track of their ...

ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who ...